Understanding immune responses in anal cancer linked to HPV.

Characterisation and harnessing the CD8+ Tissue Resident Memory T cell response in HPV-driven anal neoplasia.

NIH-funded research University of New South Wales · NIH-10435548

This study is looking at how certain immune cells in the body help protect against precancerous changes in the anal area caused by high-risk HPV, especially in people living with HIV, and it needs tissue samples and health information from patients to better understand how to prevent these changes from turning into anal cancer.

Quick facts

Grant typeR21 grant
Study typeNIH-funded research
Funding institutionUniversity of New South Wales NIH-funded
Lab location1 site (Sydney, Australia)
Project IDNIH-10435548 on NIH RePORTER

What this research studies

This research investigates how specific immune cells, known as CD8+ tissue resident memory T cells, respond to precancerous lesions in the anal region caused by high-risk human papillomavirus (HPV). By analyzing tissue samples from HIV-infected individuals, the study aims to uncover the mechanisms that prevent the progression of these lesions to anal cancer. The research utilizes existing clinical data and tissue archives from a previous study, focusing on the role of these immune cells in controlling disease progression. Patients may be involved in providing tissue samples and clinical information to help advance our understanding of anal cancer immunity.

Who could benefit from this research

Good fit: Ideal candidates for this research include HIV-infected adults who have been diagnosed with high-grade squamous intraepithelial lesions (HSIL) related to HPV.

Not a fit: Patients who do not have HPV-related anal lesions or are not HIV-infected may not benefit from this research.

Why it matters

Potential benefit: If successful, this research could lead to new therapeutic strategies that enhance the immune response against anal cancer, potentially improving patient outcomes.

How similar studies have performed: Previous research has shown promising results in understanding immune responses in HPV-related cancers, suggesting that this approach could yield valuable insights.

Where this research is happening

Sydney, Australia

Researchers

About this research

  1. This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
  2. Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
  3. For full project details, budget, and progress reports, visit the official NIH RePORTER page below.
Conditions Cancers
Last reviewed 2026-06-13 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.